IP Library Granted Patent US 10,676,714
Granted Patent B2
US 10,676,714 · App. 15/894,842 · Granted Jun 9, 2020

Suspension culture of human embryonic stem cells

Inventors: Ramkumar Mandalam (Union City, CA); Yan Li (Tallahassee, FL); Isabelle Nadeau-Demers (San Francisco, CA)
Assignee: Asterias Biotherapeutics, Inc.
C12N5/0606C12N2501/115C12N2501/125C12N2501/15C12N2501/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,676,714
App. No.
15/894,842
Granted
Jun 9, 2020
Kind
B2
Abstract

This disclosure provides an improved system for culturing human embryonic stem cells. The cells are cultured in suspension so as to maximize the production capacity of the culture environment. The new culture system of this invention allows for bulk proliferation of hES cells in a more cost-effective manner, which facilitates commercial production of important products for use in human therapy.

Claims (16)

1. A method for culturing undifferentiated human pluripotent stem (hPS) cells in suspension, the method comprising:

a) suspending undifferentiated hPS cells in a cell culture medium comprising basic fibroblast growth factor (bFGF);

b) maintaining the hPS cells substantially undifferentiated while culturing in suspension;

c) changing the cell culture medium periodically; and

d) optionally splitting the culture from time to time, so as to reduce the density of the hPS cells in culture;

wherein the hPS cells are not grown attached to a solid substrate.

2. The method of claim 1 , wherein the concentration of bFGF is at least 40 ng/mL.

3. The method of claim 1 , wherein the concentration of bFGF is about 40 ng/mL.

4. The method of claim 1 , wherein the concentration of bFGF is about 80 ng/mL.

5. The method of claim 1 , wherein the cell culture medium further comprises at least one factor selected from transforming growth factor beta (TGF β) , stem cell factor (SCF), and Flt3 ligand (Flt3L).

6. The method of claim 1 , wherein the hPS cells are cultured in suspension for a period of at least two months.

7. The method of claim 1 , further comprising plating the undifferentiated hPS cells onto a solid substrate and continuing to culture the hPS cells in a substantially undifferentiated state.

8. The method of claim 1 , further comprising harvesting the undifferentiated hPS cells from the culture and differentiating them.

9. The method of claim 7 , further comprising differentiating the plated hPS cells.

10. The method of claim 1 , wherein the undifferentiated hPS cells are cultured in suspension inside a cell culture vessel that is being agitated, rocked, or spun.

11. The method of claim 1 , wherein the undifferentiated hPS cells are cultured in suspension inside a cell culture vessel selected from a spinner flask, shaker flask, a fermentor and a bioreactor.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 16, 2020
From: MANDALAM, RAMKUMAR; LI, YAN; NADEAU-DEMERS, ISABELLE
To: GERON CORPORATION
Reel/Frame 052420/0539 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 16, 2020
From: GERON CORPORATION
To: ASTERIAS BIOTHERAPEUTICS, INC.
Reel/Frame 052420/0821 →
Continuity (4)
Continuation 14791479 · Jul 6, 2015
Continuation 11917993
Provisional Application 60693266 · Jun 22, 2005
Related Publication 20190017014A1 · Jan 17, 2019
Cited By (2)
US 12,441,983 US 12,692,476